Duksan Techopia덕산테코피아

Duksan Techopia's losses have widened sharply over the past year, with trailing results deeply negative and the share price down over 50% in 12 months.

The company is a Korean fine chemical maker supplying display, semiconductor, battery and pharmaceutical intermediate materials. Trailing twelve-month revenue is about ₩140B, but operating income is about -₩46B and net income about -₩83B, with liabilities at roughly 7 times equity. Shares closed at ₩10,320, well below the 52-week high of ₩33,000.

What stands out

• Revenue has grown from ₩94B in 2023 to ₩112B in 2025, but operating losses grew from about -₩6B to -₩43B over the same period.
• Trailing free cash flow is about -₩60B, and borrowings of about ₩196B compare with cash of about ₩10B.
• Balance sheet leverage is high, with liabilities at 702% of equity and ROE at -55.6% on a trailing basis.
• Recent filings are mostly routine governance items: a shareholders' meeting, proxy documents, a record date notice, and a stock purchase option grant, plus a half-year report and IR events.
• No recent news headlines were available in the data, so the drivers of the share price fall are not explained here.
• Foreign ownership fell from 2.3% to 1.5% over 60 days, while retail investors were net buyers over the last 20 days and institutions were net sellers.

What to watch

• Upcoming shareholders' meeting and its outcomes, including any agenda items disclosed in the proxy and meeting notices.
• Next periodic filings, to see whether operating losses and negative free cash flow narrow from the trailing figures.
• Debt levels relative to cash, as the data shows borrowings far above cash on hand.